MCU-i4
Based on 8 publication(s) in Google Scholar
MCU-i4 blocks the IP3-dependent mitochondrial Ca2+-uptake, maintaining the gatekeeping role of their target.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.94%
- CAS No.: 371924-24-2
- Formule: C23H27N3O2
- Masse moléculaire:377.48
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Glucose Metabolism Compound Library
HY-L092
-
Cuproptosis Compound Library
HY-L133
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) MCU-i4
More- Autophagy. 2026 Jul 1:1-26. [Abstract]
- Nucleic Acids Res. 2026 Apr 23;54(8):gkag233. [Abstract]
- Pharmacol Res. 2026 May:227:108177. [Abstract]
- Ecotoxicol Environ Saf. 2024 Jan 1:269:115906. [Abstract]
- Int J Mol Sci. 2022 Aug 3;23(15):8629. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Dec 21. [Abstract]
- Brain Sci. 2025 Oct 28;15(11):1157. [Abstract]
- SSRN. 2025 Dec 15.
Customer Validation & Images
-
WB
-
IF
-
WB
-
Cell Imaging/Staining
-
WB
Activité biologique
MCU-i4 modulates mitochondrial Ca2+ uptake to 1 min of incubation, i.e., exerting a negative modulation, indicating that the primary effect of these compounds is a sudden and direct modulation of MCU complex activity[1].
MCU-i4 exerted a negative effect on Δψ. MCU-i4 has no effect on cell viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Growing medium of 90% confluent C2C12 myoblasts.
-
Concentration:10 μM.
-
Incubation Time:24 h.
-
Result:Decreased myotube width.
Chemical Information
-
CAS No. 371924-24-2
-
Appearance Solid
-
Masse moléculaire 377.48
-
Formule C23H27N3O2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(NC2=CC=C(N(CC)CC)C=C2)C3=CC(C)=CC=C3N=C1)OCC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
Emodin induces defensive autophagy against white spot syndrome virus infection via targeting the hemocyanin-mediated endoplasmic reticulum-mitochondrial crosstalk in shrimp. [Abstract]2026 Jul 1:1-26. PMID: 42329080 -
Nucleic Acids Res
Mitochondrial DNA replication is regulated by endoplasmic reticulum-mitochondrial contact sites, the mitochondrial calcium uniporter, and manganese. [Abstract]2026 Apr 23;54(8):gkag233. PMID: 42033228 -
Pharmacol Res
SERCA2 dysfunction drives vascular calcification via coupling with TSPO-MCU at mitochondria-associated endoplasmic reticulum membranes. [Abstract]2026 May:227:108177. PMID: 41932666 -
Ecotoxicol Environ Saf
MicroRNA-129-1-3p protects chicken granulosa cells from cadmium-induced apoptosis by down-regulating the MCU-mediated Ca2+ signaling pathway. [Abstract]2024 Jan 1:269:115906. PMID: 38176135 -
Int J Mol Sci
Effects of MICU1-Mediated Mitochondrial Calcium Uptake on Energy Metabolism and Quality of Vitrified-Thawed Mouse Metaphase II Oocytes. [Abstract]2022 Aug 3;23(15):8629. PMID: 35955764
MCU-i4 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Aug 3;23(15):8629. [Abstract]
The expression of MICU1 protein in vitrified oocytes treated with or without MCU-i4 (2 μM) was analyzed.
MCU-i4 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Aug 3;23(15):8629. [Abstract]
Effects of MCU-i4 or DS16570511 treatment on oocyte quality during vitrification and freezing; fluorescence images of MMPs in each group.
MCU-i4 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2022 Aug 3;23(15):8629. [Abstract]
Effects of MCU-i4 or DS16570511 treatment on pyruvate oxidation and energy metabolism in vitrified oocytes. Western blot analysis of p-PDH, PDH, and their expression ratios in oocytes of each group.
-
Naunyn Schmiedebergs Arch Pharmacol
Mitocurcumin induces ROS-/JNK-mediated paraptosis to overcome chemoresistance in non-small cell lung cancer. [Abstract]2025 Dec 21. PMID: 41422457 -
Brain Sci
MAM-Mediated Mitochondrial Ca2+ Overload and Endoplasmic Reticulum Stress Aggravates Synaptic Plasticity Impairment in Diabetic Mice. [Abstract]2025 Oct 28;15(11):1157. PMID: 41300164
MCU-i4 purchased from MedChemExpress. Usage Cited in: Brain Sci. 2025 Oct 28;15(11):1157. [Abstract]
MCU-i4 (0-20 μM). Western blot results of MCU protein expression.
MCU-i4 purchased from MedChemExpress. Usage Cited in: Brain Sci. 2025 Oct 28;15(11):1157. [Abstract]
Inhibiting MCU expression using MCU-i4 attenuated the high glucose-induced increase in p-IRE1α fluorescence intensity, while inhibiting IRE1α phosphorylation using 4μ8C reduced the glucose-induced increase in MCU fluorescence intensity. Immunofluorescence images of MCU and p-IRE1α proteins in hippocampal neurons.
-
Solvant et solubilité
DMSO : 12.5 mg/mL (33.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (3.31 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (3.31 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 2 mg/mL (5.30 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Giulia Di Marco, et al. A High-Throughput Screening Identifies MICU1 Targeting Compounds. Cell Rep. 2020 Feb 18;30(7):2321-2331.e6. [Content Brief]
[2]. Alessandro Rimessi, et al. Update on Calcium Signaling in Cystic Fibrosis Lung Disease. Front Pharmacol. 2021 Mar 11;12:581645. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6491 mL | 13.2457 mL | 26.4915 mL | 66.2287 mL |
| 5 mM | 0.5298 mL | 2.6491 mL | 5.2983 mL | 13.2457 mL | |
| 10 mM | 0.2649 mL | 1.3246 mL | 2.6491 mL | 6.6229 mL | |
| 15 mM | 0.1766 mL | 0.8830 mL | 1.7661 mL | 4.4152 mL | |
| 20 mM | 0.1325 mL | 0.6623 mL | 1.3246 mL | 3.3114 mL | |
| 25 mM | 0.1060 mL | 0.5298 mL | 1.0597 mL | 2.6491 mL | |
| 30 mM | 0.0883 mL | 0.4415 mL | 0.8830 mL | 2.2076 mL |
MCU-i4 Related Classifications
HY-138620 Related Classifications
Powered by Bioz